<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03085654</url>
  </required_header>
  <id_info>
    <org_study_id>UESTC-neuSCAN_10</org_study_id>
    <nct_id>NCT03085654</nct_id>
  </id_info>
  <brief_title>Multiple Dose Effect of Oxytocin on Males With High or Low Trait Anxiety</brief_title>
  <official_title>Multiple Dose Effect of Oxytocin on Males With High or Low Trait Anxiety</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Electronic Science and Technology of China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Electronic Science and Technology of China</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To examine whether multiple doses of oxytocin have different effects on behavior and neural
      indices in males with high or low trait anxiety.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the present study, healthy male subjects' trait anxiety levels will be assessed by the
      sub-trait inventory of the State-Trait Anxiety Inventory (STAI). According to subjects' trait
      anxiety scores, they will be divided into high or low anxiety experimental groups.

      Next, experiments will investigate the acute effect (single dose) and chronic effect (3 doses
      or 5 doses) of oxytocin on brain functional connectivity during resting-state and brain
      activation in response to watching emotional stimuli using functional magnetic resonance
      imaging (fMRI). Also the brain structure data (T1 and diffusion tensor imaging, DTI) of
      subjects will be collected. After finishing the scanning tasks, subjects will be required to
      rate the emotional valence, intensity and arousal of the pictures shown in the scanner.

      During the course of the study subjects will complete a number of questionnaires: Empathy
      Quotient (EQ), Cheek and Buss Shyness scale (CBSS),Interpersonal Reactivity Index
      (IRI),Childhood Trauma Questionnaire (CTQ),Beck depression inventory (BDI), State-Trait
      Anxiety Inventory (STAI), Autism Spectrum Quotient (ASQ), Liebowitz Social Anxiety Scale
      (LSAS),Positive and Negative Affect Schedule (PANAS),d2 attention test, and the Visual
      Analogue Scale for anxiety.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 3, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2017</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2017</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes between acute and chronic administration of oxytocin on amygdala activity as assessed by fMRI</measure>
    <time_frame>5 days</time_frame>
    <description>Changes in neural activity between first dose and repeated dose will be assessed over the time course of 5 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes between acute and chronic administration of oxytocin on amygdala connectivity as assessed by fMRI</measure>
    <time_frame>5 days</time_frame>
    <description>Changes in neural connectivity between first dose and repeated dose will be assessed over the time course of 5 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Interaction of acute and chronic treatment effects with trait anxiety on neural activity</measure>
    <time_frame>5 days</time_frame>
    <description>The high and low trait anxiety groups will be compared with respect to differences in the acute effects (single dose, day 1) and changes of effects with chronic treatment over the course of 5 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interaction of acute and chronic treatment effects with trait anxiety on neural connectivity</measure>
    <time_frame>5 days</time_frame>
    <description>The high and low trait anxiety groups will be compared with respect to differences in the acute effects (single dose, day 1) and changes of effects with chronic treatment over the course of 5 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of oxytocin on arousal ratings of emotional stimuli (acute and changes with chronic treatment)</measure>
    <time_frame>5 days</time_frame>
    <description>Subjects will rate arousal of emotional stimuli using Likert Scales</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of oxytocin on valence ratings of emotional stimuli (acute and changes with chronic treatment)</measure>
    <time_frame>5 days</time_frame>
    <description>Subjects will rate valence of emotional stimuli using Likert Scales</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interaction of treatment effects on valence ratings with trait anxiety (acute and changes with chronic treatment)</measure>
    <time_frame>5 days</time_frame>
    <description>The high and low trait anxiety groups will be compared with respect to differences in the acute (single dose, day 1) treatment effects and changes with chronic treatment (5 days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interaction of treatment effects on arousal ratings with trait anxiety (acute and changes with chronic treatment)</measure>
    <time_frame>5 days</time_frame>
    <description>The high and low trait anxiety groups will be compared with respect to differences in the acute (single dose, day 1) treatment effects and changes with chronic treatment (5 days)</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>High anxiety group (single dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxytocin nasal spray or placebo nasal of one dose in subjects with high trait anxiety.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High anxiety group (3 doses)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxytocin nasal spray or placebo nasal spray interleaved during the 5 days( on the 1st,3rd and 5th day),24 IU per day in subjects with high trait anxiety.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High anxiety group (5 doses)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxytocin nasal spray or placebo nasal spray for 5 days,24 IU per day in subjects with high trait anxiety.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low anxiety group (single dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxytocin nasal spray or placebo nasal spray of one dose in subjects with low trait anxiety.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low anxiety group (3 doses)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxytocin nasal spray or placebo nasal spray interleaved during the 5 days( on the 1st,3rd and 5th day),24 IU per day in subjects with low trait anxiety.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low anxiety group (5 doses)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxytocin nasal spray or placebo nasal spray for 5 days in subjects with low trait anxiety.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin nasal spray</intervention_name>
    <description>Intranasal administration of oxytocin 24 international units per dose.</description>
    <arm_group_label>High anxiety group (single dose)</arm_group_label>
    <arm_group_label>High anxiety group (3 doses)</arm_group_label>
    <arm_group_label>High anxiety group (5 doses)</arm_group_label>
    <arm_group_label>Low anxiety group (single dose)</arm_group_label>
    <arm_group_label>Low anxiety group (3 doses)</arm_group_label>
    <arm_group_label>Low anxiety group (5 doses)</arm_group_label>
    <other_name>Oxytocin treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo nasal spray</intervention_name>
    <description>Intranasal administration of placebo 24 international units per dose.</description>
    <arm_group_label>High anxiety group (single dose)</arm_group_label>
    <arm_group_label>High anxiety group (3 doses)</arm_group_label>
    <arm_group_label>High anxiety group (5 doses)</arm_group_label>
    <arm_group_label>Low anxiety group (single dose)</arm_group_label>
    <arm_group_label>Low anxiety group (3 doses)</arm_group_label>
    <arm_group_label>Low anxiety group (5 doses)</arm_group_label>
    <other_name>Placebo control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

          -  healthy adult males

        Exclusion:

          -  past or current psychiatric or neurological disorder

          -  head trauma

          -  substance abuse

          -  medication

          -  fMRI contraindications (e.g. metal implants)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keith Kendrick, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Electronic Science and Technology of China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Benjamin Becker, PhD</last_name>
    <phone>+86 2861 830 811</phone>
    <email>ben_becker@gmx.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Weihua Zhao, MSc</last_name>
    <phone>+86 2861 830 811</phone>
    <email>zarazhao.uestc@outlook.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>school of life science and technology, University of Electronic Science and Technology of China</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610054</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weihua Zhao, Master</last_name>
      <email>zarazhao.uestc@outlook.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2016</study_first_submitted>
  <study_first_submitted_qc>March 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2017</study_first_posted>
  <last_update_submitted>March 14, 2017</last_update_submitted>
  <last_update_submitted_qc>March 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Electronic Science and Technology of China</investigator_affiliation>
    <investigator_full_name>Keith Kendrick</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>multiple doses</keyword>
  <keyword>oxytocin</keyword>
  <keyword>trait anxiety</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

